Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.

What is known and objective Anticoagulation therapy with warfarin requires periodic monitoring of prothrombin time-international normalized ratio ( PT- INR) and adequate dose adjustments based on the data to minimize the risk of bleeding and thromboembolic events. In our hospital, we have developed...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 42; no. 5; pp. 591 - 598
Autores principales: Katada, Y., Nakagawa, S., Minakata, K., Odaka, M., Taue, H., Sato, Y., Yonezawa, A., Kayano, Y., Yano, I., Nakatsu, T., Sakamoto, K., Uehara, K., Sakaguchi, H., Yamazaki, K., Minatoya, K., Sakata, R., Matsubara, K.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124971317&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 124971317
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Oct2017
      vid: 42
      iid: 5
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        124971317
        124971317
        124971317
        10.1111/jcpt.12560
        124971317
      ppf: 591
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.
      aug:
        au:
          Katada, Y.
          Nakagawa, S.
          Minakata, K.
          Odaka, M.
          Taue, H.
          Sato, Y.
          Yonezawa, A.
          Kayano, Y.
          Yano, I.
          Nakatsu, T.
          Sakamoto, K.
          Uehara, K.
          Sakaguchi, H.
          Yamazaki, K.
          Minatoya, K.
          Sakata, R.
          Matsubara, K.
        affil: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto Japan
      sug:
        subj:
          Warfarin Administration and Dosage
          Treatment Outcomes
          Surgery, Cardiovascular
          Protocols
          Human
          Male
          Female
          Warfarin Pharmacodynamics
          Postoperative Complications
          P-Value
          Male
          Female
      ab: What is known and objective Anticoagulation therapy with warfarin requires periodic monitoring of prothrombin time-international normalized ratio ( PT- INR) and adequate dose adjustments based on the data to minimize the risk of bleeding and thromboembolic events. In our hospital, we have developed protocol-based pharmaceutical care, which we called protocol-based pharmacotherapy management ( PBPM), for warfarin therapy. The protocol requires pharmacists to manage timing of blood sampling for measuring PT- INR and warfarin dosage determination based on an algorithm. This study evaluated the efficacy of PBPM in warfarin therapy by comparing to conventional pharmaceutical care. METHODS From October 2013 to June 2015, a total of 134 hospitalized patients who underwent cardiovascular surgeries received post-operative warfarin therapy. The early series of patients received warfarin therapy as the conventional care (control group, n=77), whereas the latter received warfarin therapy based on the PBPM ( PBPM group, n=68). These patients formed the cohort of the present study and were retrospectively analysed. RESULTS The indications for warfarin included aortic valve replacement (n=56), mitral valve replacement (n=4), mitral valve plasty (n=22) and atrial fibrillation (n=29). There were no differences in patients' characteristics between both groups. The percentage time in therapeutic range in the first 10 days was significantly higher in the PBPM group (47.1%) than that in the control group (34.4%, P<.005). The average time to reach the steady state was significantly ( P<.005) shorter in the PBPM group compared to the control group (7.3 vs 8.6 days). What is new and conclusion Warfarin therapy based on our novel PBPM was clinically safe and resulted in significantly better anticoagulation control compared to conventional care.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N